Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.50 |
| ▸ | FNTB | P49356 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.46 |
| ▸ | SQLE | Q14534 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16174588 | 1.00 | FNTA (0.50) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16174573 | 0.84 | ALDH1A1 (0.49) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16167395 | 0.84 | ALDH1A1 (0.49) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16167397 | 0.84 | ALDH1A1 (0.49) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16428262 | 0.83 | FNTA (0.61) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16167488 | 0.83 | FNTA (0.61) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16167489 | 0.83 | FNTA (0.61) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL16428592 | 0.81 | KDM4E (0.60) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL11578341 | 0.80 | KDM4E (0.58) | FNTAFNTBKMT2AALDH1A1ALOX15 | |
| SCHEMBL10181090 | 0.80 | KDM4E (0.58) | FNTAFNTBKMT2AALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663440-B2 | Cross metathesis of poly-branched poly-olefins | MATERIA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160107980-A1 | CROSS METATHESIS OF POLY-BRANCHED POLY-OLEFINS | MATERIA, INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107980-A1 | CROSS METATHESIS OF POLY-BRANCHED POLY-OLEFINS | COASY, SQLE, FDFT1 | FNTA 5/4885FNTB 7/4885KMT2A 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.